Filtered By:
Drug: Activase
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 1186 results found since Jan 2013.
Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke
Conclusions: Patients with increasing age, a higher baseline systolic blood pressure, and previous ischemic stroke were at a higher odd of receiving a low-dose of alteplase. The low-dose was associated with a lower risk of developing symptomatic intracranial hemorrhage.PMID:36313231 | PMC:PMC9608043 | DOI:10.7150/ijms.76105
Source: International Journal of Medical Sciences - October 31, 2022 Category: Biomedical Science Authors: Jie Chen Hangfeng Li Hanhan Lei Shuangfang Fang Qilin Yuan Yangui Chen Dongping Chen Ronghua Chen Yixian Zhang Jin Wei Guangliang Chen Zhiting Chen Nan Liu Hou-Wei Du Source Type: research
Is tenecteplase a viable alternative to alteplase in the treatment of acute ischemic stroke ?
Anand Girish VaishnavAnnals of Indian Academy of Neurology 2022 25(5):794-795
Source: Annals of Indian Academy of Neurology - October 31, 2022 Category: Neurology Authors: Anand Girish Vaishnav Source Type: research
Tenecteplase and alteplase for thrombolysis of acute ischemic stroke within 4.5 hours: An efficacy and safety study
Conclusions: This study showed a comparable efficacy and safety profile of alteplase and TNK in thrombolysis of AIS throughout the 4.5 hours window period. Moreover, the ease of administration and better pharmacodynamic properties favors tenecteplase.
Source: Annals of Indian Academy of Neurology - October 31, 2022 Category: Neurology Authors: Nikita Dhar Mritunjai Kumar Ashutosh Tiwari Ishita Desai Govind Madhaw Niraj Kumar Source Type: research
Intravenous thrombolysis in CADASIL: report of two cases and a systematic review
ConclusionsAvailable data on intravenous thrombolysis in CADASIL patients are scarce but suggest that this treatment can be taken into consideration for these patients.
Source: Neurological Sciences - October 18, 2022 Category: Neurology Source Type: research
Prevalence, risk factors, and clinical outcomes of remote intracerebral hemorrhage after intravenous thrombolysis in acute ischemic stroke: a systematic review and meta-analysis
ConclusionsAlthough rICH is uncommon after intravenous thrombolysis, its presence can lead to worse functional outcomes and higher mortality in acute ischemic stroke. Patients at high risk of rICH must be identified based on potential risk factors.
Source: Journal of Neurology - October 5, 2022 Category: Neurology Source Type: research
Endovascular thrombectomy with or without intravenous alteplase in acute stroke: a systematic review and meta-analysis of randomized clinical trials
ConclusionsNo statistical difference was found in functional and safety outcomes between direct EVT and bridging therapy groups in acute stroke within 4.5 h after symptom onset. EVT alone was non-inferior to bridging therapy for several, but not the more stringent, non-inferiority margins.
Source: Journal of Neurology - October 5, 2022 Category: Neurology Source Type: research
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. eCollection 2022 Aug.ABSTRACTIntravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mounting evidence to support the routine use of Tenecteplase (TNK) to treat acute ischemic stroke. TNK is a genetically modified tPA with higher fibrin specificity, longer half-life, and reduced systemic coagulopathy. In this il...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Annie Zhu Phavalan Rajendram Eric Tseng Shelagh B Coutts Amy Y X Yu Source Type: research
